International Journal of Innovative Technologies in Social Science · Nov 4, 2026

EFFICACY AND SAFETY OF NON-HORMONAL NK- 3 RECEPTOR ANTAGONISTS FOR VASOMOTOR SYMPTOMS OF MENOPAUSE: A SYSTEMATIC REVIEW

By Światlak K, Trzaskalik J, Żelazna W et al.

Background: Vasomotor symptoms (VMS) affect up to 80% of menopausal women. Estrogen withdrawal-induced hyperactivity of hypothalamic KNDy neurons makes NK3 receptor antagonism a targeted non-hormonal therapeutic strategy. Aim: To evaluate the efficacy, impact on sleep and quality of life, and safety (specifically liver function) of NK3 receptor antagonists for moderate-to-severe menopausal VMS. Materials and methods: A PRISMA-guided systematic search across PubMed and Scopus (July 15, 2026) yielded 412 records, screened independently by five reviewers via Rayyan. Randomized controlled trials and cohort studies evaluating NK3 antagonists (fezolinetant, elinzanetant, pavinetant, GS1-144) versus placebo in peri-/postmenopausal women were included. Key outcomes were VMS frequency/severity, sleep (PROMIS SD), quality of life (MENQOL), and adverse events. Results: NK3 antagonists significantly and rapidly reduced VMS frequency and severity versus placebo, with sustained efficacy up to 52 weeks. Subjective sleep quality and MENQOL scores consistently improved, including in breast cancer patients on endocrine therapy. Side effects were predominantly mild (gastrointestinal, neurological) with no endometrial risks. Asymptomatic, transient transaminase elevations (>3×ULN) occurred as the primary adverse event, resolving upon discontinuation. Conclusion: NK3 receptor antagonists are a highly effective, non-hormonal treatment for moderate-to-severe VMS that substantially improve sleep and quality of life. Periodic liver function monitoring is recommended due to potential transient transaminase elevations.

doi.org/10.31435/ijitss.4(52).2026.6780Open accessInterventions

AgingResearch.News